The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations

Abstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) h...

Full description

Bibliographic Details
Main Authors: Hua Luo, Hongguo Chen, Chang Liu, Siyuan Zhang, Chi Teng Vong, Dechao Tan, Yuntao Dai, Yitao Wang, Shilin Chen
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Chinese Medicine
Subjects:
Online Access:https://doi.org/10.1186/s13020-021-00483-6
id doaj-9952cb39dc584cd599bc4a9a20274096
record_format Article
spelling doaj-9952cb39dc584cd599bc4a9a202740962021-08-08T11:09:09ZengBMCChinese Medicine1749-85462021-08-0116111410.1186/s13020-021-00483-6The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparationsHua Luo0Hongguo Chen1Chang Liu2Siyuan Zhang3Chi Teng Vong4Dechao Tan5Yuntao Dai6Yitao Wang7Shilin Chen8Macau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauKey Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical SciencesMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauKey Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical SciencesAbstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) has aroused profound impetus in the investigation of TCM and attracted global attention to the ancient books of TCM. Three new medicines for the treatment of COVID-19 derived from Chinese Classical Formula (经典名方, CCF) have been approved in 2021 due to their effectiveness for the treatment of COVID-19. This article introduced the research background of CCF pharmaceutical preparation (CCFPP), explained the ideas for the modernization of CCF and analyzed related issues involved in the development process of CCFPP, including the origin of medicinal materials, processing methods, dosages and the preparation process of CCF Material Reference. The strategy for industrialization was proposed in terms of the evaluation of the pharmaceutical properties, industrialization considerations, and clinical positioning of CCFPP. The key contents and requirements for the development CCFPP were also summarized according to the recently published registration guidance by the Center for Drug Evaluation in China. In addition, the safety issues of CCFPP were described, including the discussion on the non-clinical safety evaluation and analyzation on the international registration of Traditional herbal medicines. This article is aimed to provide references for enterprises, researchers, and relevant personnel of government departments that are engaged in the development of CCF to speed up the developing process of CCFPP.https://doi.org/10.1186/s13020-021-00483-6Chinese Classical FormulasMaterial ReferenceOrigin of the medicinal materialsProcessing methodsDosage verificationQuality control
collection DOAJ
language English
format Article
sources DOAJ
author Hua Luo
Hongguo Chen
Chang Liu
Siyuan Zhang
Chi Teng Vong
Dechao Tan
Yuntao Dai
Yitao Wang
Shilin Chen
spellingShingle Hua Luo
Hongguo Chen
Chang Liu
Siyuan Zhang
Chi Teng Vong
Dechao Tan
Yuntao Dai
Yitao Wang
Shilin Chen
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
Chinese Medicine
Chinese Classical Formulas
Material Reference
Origin of the medicinal materials
Processing methods
Dosage verification
Quality control
author_facet Hua Luo
Hongguo Chen
Chang Liu
Siyuan Zhang
Chi Teng Vong
Dechao Tan
Yuntao Dai
Yitao Wang
Shilin Chen
author_sort Hua Luo
title The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
title_short The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
title_full The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
title_fullStr The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
title_full_unstemmed The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
title_sort key issues and development strategy of chinese classical formulas pharmaceutical preparations
publisher BMC
series Chinese Medicine
issn 1749-8546
publishDate 2021-08-01
description Abstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) has aroused profound impetus in the investigation of TCM and attracted global attention to the ancient books of TCM. Three new medicines for the treatment of COVID-19 derived from Chinese Classical Formula (经典名方, CCF) have been approved in 2021 due to their effectiveness for the treatment of COVID-19. This article introduced the research background of CCF pharmaceutical preparation (CCFPP), explained the ideas for the modernization of CCF and analyzed related issues involved in the development process of CCFPP, including the origin of medicinal materials, processing methods, dosages and the preparation process of CCF Material Reference. The strategy for industrialization was proposed in terms of the evaluation of the pharmaceutical properties, industrialization considerations, and clinical positioning of CCFPP. The key contents and requirements for the development CCFPP were also summarized according to the recently published registration guidance by the Center for Drug Evaluation in China. In addition, the safety issues of CCFPP were described, including the discussion on the non-clinical safety evaluation and analyzation on the international registration of Traditional herbal medicines. This article is aimed to provide references for enterprises, researchers, and relevant personnel of government departments that are engaged in the development of CCF to speed up the developing process of CCFPP.
topic Chinese Classical Formulas
Material Reference
Origin of the medicinal materials
Processing methods
Dosage verification
Quality control
url https://doi.org/10.1186/s13020-021-00483-6
work_keys_str_mv AT hualuo thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT hongguochen thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT changliu thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT siyuanzhang thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT chitengvong thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT dechaotan thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT yuntaodai thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT yitaowang thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT shilinchen thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT hualuo keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT hongguochen keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT changliu keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT siyuanzhang keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT chitengvong keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT dechaotan keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT yuntaodai keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT yitaowang keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
AT shilinchen keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations
_version_ 1721216300450054144